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Abstract These are the first experiments to study the effect of 
in vivo expression of the Na/K-ATPase ot2 subunit which serves 
as a receptor for cardiac glycosides. The ct2 subunit is not 
normally expressed in rat liver, so hepatocytes which lack 
endogenous <x2 protein are a logical first target to study the 
effects of a2 expression on membrane Na/K-ATPase activity. At 
3 days after ot2 adenovirus vector infusion, Wistar rat livers 
contained ct2 DNA, ct2 mRNA, and a2 protein. Rat liver 
membrane ouabain binding activity and the sensitivity of Na/K-
ATPase activity to ouabain significantly increased. Total 
membrane Na/K-ATPase was regulated at a constant level while 
expressed a2 activity represented 10% of the total active Na/K-
ATPase sites in a2 transduced rat liver. These studies are the 
first to establish a paradigm in which an endogenous drug 
receptor is expressed to alter cellular pharmacologie sensitivity. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
The Na/K-ATPase or sodium pump is an intrinsic plasma 
membrane enzyme which hydrolyzes ATP to maintain the 
transmembrane gradients of Na+ and K+ found in mamma-
lian cells [1-6]. This enzyme is the functional drug receptor for 
cardiac glycosides. The enzyme consists of two noncovalently 
linked subunits. The a subunit (about 112 kDa) contains all 
of the ligand binding sites of the enzyme, and the ß subunit 
(about 55 kDa) is a glycoprotein that is essential for normal 
assembly and function of the enzyme [4-6]. Three a subunits 
have been identified and functionally characterized. The most 
striking differences between ocl, oc2 and oc3 are their different 
sensitivities to cardiac glycosides and oxygen free radicals, and 
their tissue distribution patterns [4-9]. In vitro, the a2 and oc3 
isoforms are known to be highly sensitive to ouabain and 
oxidants, while cd is relatively insensitive to ouabain and 
oxidants. The a l subunit serves a housekeeping function 
maintaining the transmembrane electrical potential for most 
cells, while the oc2 and ot3 isoforms are expressed in a tissue-
specific distribution. oe2 and a3 are mainly expressed in the 
brain and heart. 
In the heart, Na/K-ATPase serves as a receptor for cardiac 
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glycosides, and a partial inhibition of the enzyme by these 
drugs increases cardiac contractility [1-3]. Recent studies 
have demonstrated that endogenous expression of a2 and 
oc3 isoforms of Na/K-ATPase is down-regulated by hypertro-
phy, hypertension, and congestive heart failure in intact hearts 
of several species [10-16]. Ouabain induces cardiac immediate 
early gene expression at doses which only inhibit a2 and oc3 
isoforms of Na/K-ATPase [17], demonstrating that ouabain 
binding to cc2 and cc3 isoforms plays an important role in 
ouabain-induced cardiac gene regulation in addition to its 
ionotropic effects. 
To further address the role of the oc2 Na/K-ATPase isoform 
as a drug receptor and glycoside-regulated membrane pump, 
it was interesting to develop an approach to express this iso-
form in vivo. Adenovirus-mediated gene therapy is under de-
velopment for the treatment of a variety of inherited and 
acquired diseases [18-24]. Replication-deficient adenoviruses 
are one of the highest efficacy gene transfer vectors for ex-
pressing recombinant genes in vivo by somatic gene transfer 
[25]. Adenoviral vectors were selected to transfer and express 
the cc2 cDNA as they effectively deliver genes in vivo to 
muscle and liver. Rat liver does not normally express the cc2 
isoform of Na/K-ATPase [26], so the absence of a background 
endogenous signal makes hepatocytes a logical initial target to 
study the effects of ex2 expression on membrane Na/K-ATPase 
activity. 
Rapid advances are being made in our understanding of 
Na/K-ATPase function and the development of adenovirus 
vectors for in vivo gene transfer. The current study was per-
formed to explore the utility of adenovirus-mediated gene 
transfer to express the rat a2 subunit in vivo and determine 
the pharmacologie effects of oc2 expression to alter the oua-
bain sensitivity of an endogenous drug receptor, the Na/K-
ATPase pump. 
2. Materials and methods 
2.1. Vector specifications, amplification and purification 
The in vivo Na/K-ATPase activity conferred by an a2 adenoviral 
vector (H5.010CMVa2) and a negative control ß-galactosidase expres-
sion vector (H5.010CMV/acZ) were compared in this study (routine 
vector nomenclature [27]). These vectors are replication-defective ad-
enoviral vectors based on a human Ad5 sub360 serotype viral ge-
nomic backbone in which sequences spanning the Ela, Elb, and 
E3b regions are deleted, with the El deletions resulting in the im-
paired ability of this virus to replicate in non-permissive cells [20]. 
The cytomegalovirus immediate early promoter and enhancer were 
cloned into the parent plasmid pAdBgl II to generate the proviral 
plasmid which was then used to make the oc2 adenovirus vector 
used in this study (pAdCMVa2) [20,28]. The identity of recombinant 
clones was verified by restriction analysis of viral DNA minipreps and 
Southern blot analysis, and all vectors were purified through two 
rounds of plaque purification. Virus was purified from 293 cell lysates 
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by cesium chloride gradient ultracentrifugation then de-salted by dial-
ysis to HBS [22]. Purified virus was used immediately for in vivo 
injections via the portal vein. Titers were determined by OD260 and 
standard plaque assay, and were approximately 1 X1013 particles/ml 
(œ lXlO 1 1 plaque-forming units (pfu)/ml). All adenoviral prepara-
tions were shown to be free of El function by absence of replication 
on HeLa cells, and PCR amplification of the El region was performed 
to exclude reconstitution of the El genome from 293 cells in the 
prepared vectors (data not shown). 
2.2. Intraportal vein injections 
Animal experiments were performed in accordance with institution-
al guidelines at the University of Michigan. Adult 200 g Wistar rats 
were anesthetized with ketamine/rompun, and the abdominal area was 
scrubbed with povidone/iodine. Using sterile technique and a mid-
line approach, 5X109 pfu of adenoviral vector suspension in HBS 
was infused into the portal vein. Four animals were infused 
with H5.010CMV/acZ and four animals were infused with 
H5.010CMVoc2. Pressure was applied for 5 min to achieve hemostasis. 
At 3 days post infusion animals from each group were anesthetized 
and livers were divided with samples from each lobe frozen on liquid 
nitrogen and stored at —80°C until analysis. Liver samples were an-
alyzed for the presence of vector DNA and transgene expression. 
2.3. Southern blot hybridization 
Samples were restricted with BamHl and probed with a random 
primer labeled 2.7 kb BamHl a2 cDNA fragment of pAdCMVa2. 
Southern blot hybridization was performed as previously described 
[29]. 
2.4. Northern blot hybridization 
RNA was extracted, electrophoresed, and hybridized with the a2 
probe described above [29]. The blot was subsequently stripped and 
reprobed using an 18S ribosomal RNA probe to demonstrate uniform 
lane loading and RNA integrity. 
2.5. Membrane preparations 
Liver membrane was prepared by a modification of previously de-
scribed methods [30]. Frozen rat liver samples (2 g) were homogenized 
in 2 volumes each of ice-cold 1 mM NaHCC"3, pH 7.50, using 20 
strokes of a loose-fitting Dounce homogenizer. The homogenates 
were diluted and filtered through 3 layers of surgical gauze. After 
centrifugation at 1500Xg for 10 min, the pellets were resuspended 
in buffer and 5.5 volumes of 70.7% sucrose were added, mixed, and 
then distributed into centrifuge tubes. 8 ml of 48.2% and 4 ml of 
42.5% sucrose were layered over this suspension. After centrifuging 
for 60 min at 66000Xg, the material which accumulated around the 
interface of 42.5% and 48.2% sucrose was collected, diluted, and 
washed. The final pellet was resuspended in 0.25 M sucrose, 30 mM 
histidine, 1 mM EDTA (pH 6.8), and stored at -80°C. Enzyme ac-
tivities were highly reproducible using this technique. 
2.6. Immunotransblot analysis 
The antibodies used in this study were rabbit isoform-specific anti-
rat a l or a2 polyclonal antibodies obtained from UBI (Waltham, 
MA). Immunotransblots were performed on liver membrane protein 
preparations as described [8,15]. 
2.7. A TPase activity assay 
Na/K-ATPase activity was assayed at 37°C by measuring the initial 
rate of release of 32P from [y-32P]ATP in a solution containing 100 
mM NaCl, 25 mM KC1, 3 mM MgCl2, 1 mM EGTA, 2 mM ATP, 
5 mM NaN3, and 50 mM Tris-HCl (pH 7.4) [31,32]. Each ATPase 
assay was done with a 15 min pre-incubation in the presence and 
absence of 1 mM ouabain to assess the ouabain-sensitive component 
of the activity. 
2.8. [y-32PJATP phosphorylation assay 
To estimate the total active Na/K-ATPase sites in the membrane 
preparation, the maximal level of the enzyme's phosphointermediate 
was determined [31,32]. Phosphorylation by [y-32P]ATP was done at 
0°C by incubating the membrane preparation with 2 mM MgCl2, 100 
mM NaCl, 10 uM ATP, and 50 mM Tris-HCl (pH 7.4) for 30 s. 
Phosphorylation reactions performed under these conditions were 
noted to be sufficient to achieve the maximal level of phosphointer-
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mediate formation. Labeling reactions performed in the presence of 
KC1 instead of NaCl were used to determine the Na+-dependent 
component of phosphorylation. After denaturation with perchloric 
acid, the samples were filtered through a 0.45 mm membrane filter, 
washed, and counted [31]. 
2.9. Ouabain binding assay 
The maximal level of bound ouabain was assayed as described 
previously using a saturating concentration (0.4 u,M) of [3H]ouabain 
in the presence of 3 mM MgCl2, 3 mM Pi (added as Tris phosphate, 
25 mM Mes, 25 mM Tris, pH 7.0). After incubation at 37°C for 15 
min, the samples were cooled on ice, and 50 ug of membrane protein 
was placed on each 0.45 mm membrane filter which was washed, air-
dried, and counted [31,32]. Non-specific binding was corrected by 
determining binding in the presence of 1 mM unlabeled ouabain. 
Protein concentration was determined with BSA used as a standard 
[33]. 
3. Results 
3.1. Adenoviral vector DNA and RNA were detected 3 days 
post injection 
Fig. 1 is a representative Southern hybridization which 
demonstrated nonrearranged cx2 adenoviral vector sequences 
in Wistar rat livers infused via the portal vein with 5 X 109 pfu 
of H5.010CMVrx2. Transduction efficiency was approximately 
5 copy number at 3 days post infusion, consistent with the 
1 2 3 4 5 
Fig. 1. Representative Southern analysis of transduced Wistar rat 
livers for a2 DNA. Wistar rat livers were transfected with 
H5.010CMV/acZ (control) or H5.010CMVa2 and analyzed for the 
presence of nonrearranged vector derived oc2 sequences in prepara-
tions of total cellular DNA probed for a2 as described in Section 2. 
The first three lanes contain DNA (10 ug) from mock infused livers 
supplemented with copy number controls: (1) 10 copy number (75 
pg of pAdCMVcû), (2) 1 copy number (7.5 pg of pAdCMVoc2), 
(3) 0 copy number. The next lane (4) contains genomic DNA (10 u.g) 
from Wistar rat liver transduced with H5.010CMV/acZ 3 days post 
infusion as labeled. Finally, the last lane (5) contains genomic DNA 
(10 ug) from Wistar rat liver transduced with H5.010CMVa2 
3 days post infusion, as labeled. The sequence specific bands ap-
peared at the predicted MW, 2700 bp. Faint hybridization noted 
with a band of lower molecular weight sequences in control and ex-
perimental animals likely reflects cross hybridization with genomic 
DNA. Note the absence of a 2700 bp band in the lanes containing 
0 copy number and H5.010CMV/acZ transduced genomic DNA 
preparations. 
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hepatocyte transfection capability of adenoviral vectors. No 
2700 bp bands, the predicted size of an a2 BamHl fragment, 
were ever detected hybridizing with the oc2 probe in Wistar rat 
liver at 3 days post infusion with H5.010CMV/acZ. Control 
infusions with the H5.010CMV/acZ adenovirus vector using 
equal doses (pfu) to the a2 adenovirus vector demonstrated 
comparable transduction efficiencies to H5.010CMVoc2 in-
fused livers as determined by ß-galactosidase staining of cells 
(data not shown). 
Livers infused via the portal vein with the specified vectors 
were analyzed for transgene expression by RNA blot hybrid-
B 
Fig. 3. Na/K-ATPase al and a2 subunit immunotransblot analysis 
of rat liver membranes following transfection with adenoviral vec-
tors with heart membrane proteins included as a positive control. 
Aliquots of membrane proteins (liver, 60 |ig/lane; heart, 30 |ig/lane) 
were separated by SDS/PAGE (10% gel) and transferred to nitrocel-
lulose. Lane 1, rat heart; lane 2, H5.010CMVo:2 transduced liver; 
lane 3, control H5.010CMV/acZ transduced liver. A: Probed with 
an al specific antibody. B: Probed with an a2 specific antibody. 
Molecular weights as determined by pre-stained molecular weight 
markers are shown on the right. Note the presence of a2 protein in 
the a2 transduced rat liver membranes and its absence in control 
lacZ transduced liver. Note the presence of endogenous al signal in 
all three samples demonstrating the integrity of the preparations. 
B 
Fig. 2. Representative Northern blot hybridization of total cellular 
RNA extracted from Wistar rat livers following transfection with 
a2 and lacZ adenoviral vectors. Wistar rat livers were control trans-
fected or transfected with H5.010CMVa2. Both lanes contain total 
cellular RNA, 15 |ig per lane. The left lane (1) contains RNA from 
a liver 3 days post transduction with H5.010CMV/ÖCZ, while the 
right lane (2) contains total cellular RNA derived from Wistar rat 
livers 3 days post transduction with H5.010CMVa2. Note the pres-
ence of sequence specific hybridization to a2 transduced liver (A, 4 h 
exposure). The sequence specific hybridization appeared at the ap-
propriate size for a2 message in a2 transduced liver. The migration 
of ribosomal RNAs is indicated along the lefthand border. The blot 
was stripped and reprobed with an 18S ribosomal RNA probe to 
document uniformity of lane loading (B). 
ization of total cellular RNA (Fig. 2A). RNA hybridization of 
total cellular RNA from Wistar rat liver demonstrated abun-
dant a2 mRNA in H5.010CMVa2 infused livers. Transfected 
Wistar rat livers at 3 days post infusion showed clear al 
mRNA sequence-specific hybridization. The distinct band de-
tected in a2 transduced livers was approximately 3.1 kb, the 
anticipated band size for transcripts initiated at the internal 
CMV promoter-enhancer of the adenovirus vector. Hybrid-
ization to an 18S ribosomal probe demonstrated uniform con-
tent of RNA in the designated lanes (Fig. 2B). 
3.2. Immunotransblot analysis demonstrates a2 protein in rat 
liver membranes following infusion of H5.010CMVa2 
Expression of cc2 protein was assessed by immunotransblot 
analysis (Fig. 3B). The antibody utilized in this assay is iso-
form-specific for the al subunit of rat Na/K-ATPase [11]. 
Specific reactivity to the oe2 isoform antibody was observed 
in H5.010CMVa2 transfected Wistar rat livers at 3 days post 
infusion. Negative control membranes which differed only in 
the substitution of the ß-galactosidase vector for the oc2 vector 
demonstrated no reactivity to this antibody consistent with al 
specificity of the detected signal. Rat heart was utilized as a 
source of al protein for a positive control since rat heart 
normally expresses the al isoform of Na/K-ATPase. The al 
isoform represents about 20% of total Na/K-ATPase in the 
heart [6,14]. The level of al expression in al transduced liver 
in comparison to ß-galactosidase transduced liver and control 
rat heart is consistent with the ouabain binding activity shown 
in Table 1. As a further control to demonstrate the isoform 
specificity of the immunotransblot results, an antibody specific 
for the a l subunit of rat Na/K-ATPase was utilized to sim-
ilarly probe the samples for a l protein (Fig. 3A). 
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Table 1 
Comparison of ouabain binding activity between Ad CMYlacZ and 
Ad CMVa2 transduced liver membrane preparations 
Experiment Ad CMVlacZ (pmol/mg) Ad CMVa2 (pmol/mg) 
N.D. 
0.08 ±0.03 
0.06 ±0.04 
N.D. 
0.62 ±0.08 
1.40 ±0.06 
0.92 ±0.09 
0.66 ±0.09 
Ouabain binding assays were done in four independent membrane 
preparations as described in Section 2. Values are mean ± standard 
error. N.D., not detectable. 
3.3. Ouabain binding assay demonstrates functional o2 protein 
in Wistar rat livers following gene transfer via the portal 
vein with H5.010CMVa2 
As a first assay to determine if expressed al protein exhibits 
similar functional properties to native oc2 protein, ouabain 
binding activity was measured. In agreement with the fact 
that rat liver expresses only the ouabain-insensitive cxl iso-
form [26], high affinity ouabain binding was negligible in liver 
membranes from rats transduced with the negative control 
vector, H5.010CMV/acZ (Table 1). In four separate experi-
ments, H5.010CMVoe2 transduction resulted in a significant 
increase in ouabain binding activity in rat liver membrane 
preparations. In agreement with the Western blot data, 
H5.010CMVa2-induced ouabain binding activity in the liver 
is lower than that seen in the rat heart preparation (data not 
shown). 
3.4. Sensitivity of Na/K-ATPase activity to ouabain increases 
following transduction of rat liver with H5.010CMVa2 
Liver membranes from Wistar rats transduced with 
H5.010CMVa2 and Wistar rats transduced with 
H5.010CMV/acZ were prepared and assayed for total Na/ 
K-ATPase activity. While H5.010CMVa2 transduction did 
not increase the total enzyme activity (Table 2), an ouabain-
sensitive portion of the enzyme was found in H5.010CMVoc2 
transduced rat liver (Fig. 4). The dose-response relationship of 
ouabain and total Na/K-ATPase activity clearly demonstrates 
a shift in ouabain sensitivity in oc2 transduced liver (Fig. 4). 
To determine the ratio of the expressed cc2 to endogenous 
a l in transduced rat liver, both ouabain binding assays and 
ATP phosphorylation assays were performed and compared. 
Since the ATP phosphorylation assay measures the total ac-
tive enzyme sites in the membrane preparation while ouabain 
binding represents the expressed active oc2 sites, the ratio of 
expressed oc2 to the total active enzyme sites was calculated. 
Expressed a2 activity represented approximately 10% of the 
total active Na/K-ATPase sites in a2 transduced rat liver, 
while lacZ transduced rat liver had no detectable al activity 
in accord with the known tissue distribution of this enzyme 
[26]. These results were consistent with the ouabain binding 
data (Table 1). 
4. Discussion 
These are the first studies to apply adenovirus-mediated 
gene transfer to a new paradigm in which endogenous drug 
receptor expression (EDRE) is employed to alter the pharma-
cologie sensitivity to a classical drug like digitalis. It was of 
interest to express the al cDNA Na/K-ATPase isoform and 
examine its in vivo function. Although active Na/K-ATPase 
has been successfully expressed in vitro in Xenopus oocytes, 
several mammalian cell lines, yeast, and insect cells using a 
variety of expression vectors [5,16,17], in vivo expression with 
these gene transfer systems has not been successful. This is the 
first study to demonstrate the feasibility of using recombinant 
adenovirus-mediated gene transfer to express a functional Na/ 
K-ATPase isoform in vivo and study its effects on Na/K-AT-
Pase membrane activity. 
Wistar rat liver does not express any a2 isoform of Na/K-
ATPase normally [26]. Hence, detection of al protein and 
function in liver is uncomplicated by background endogenous 
al protein expression as it would be in cardiac muscle. The 
ability of the al isoform to augment membrane Na/K-AT-
Pase sensitivity to ouabain following gene transfer in vivo had 
not been previously demonstrated. 
DNA blot analysis demonstrated transfer of the al cDNA 
following in vivo infusion of the al adenoviral expression 
vector H5.010CMVa2. RNA blot analysis demonstrated 
that al mRNA is expressed in rat liver at 3 days post 
H5.010CMVa2 vector infusion. Western blot analysis of pro-
tein derived from liver membranes demonstrated immuno-
reactivity corroborating expression of al protein. DNA, 
RNA and protein blots were consistent. As controls, trans-
ductions performed with H5.010CMV/acZ did not result in 
expression of al mRNA or al protein excluding adenovirus 
induced changes in the expression of the endogenous al gene 
as the mechanism of protein production. It was established 
that the expressed al was a functional protein, the demon-
stration of protein function was important as the expression 
of largely dysfunctional, misfolded proteins has typified some 
prokaryotic and in vitro expression systems. 
Ouabain binding assays showed that expressed al binds 
ouabain with high affinity, and its Na/K-ATPase activity is 
highly ouabain sensitive in comparison to that of the endog-
enous a l isoform. The efficacy of the expressed al isoform to 
augment ouabain binding activity in vivo represents a further 
validation of the putative function of the al isoform as a high 
affinity receptor for cardiac glycosides. These findings are con-
sistent with previous in vitro studies which suggested the al 
isoform as a major high affinity ouabain sensitive isoform 
[5,16,17]. It was interesting that total cellular Na/K-ATPase 
activity remained constant even when al activity was ex-
pressed using a constitutive promoter. This suggests that 
transgene derived Na/K-ATPase activity down regulates en-
dogenous Na/K-ATPase activity to maintain total cellular ac-
tivity constant. These observations had not been previously 
Table 2 
Specific Na/K-ATPase activity and estimation of the ratio of expressed a2 to the total active enzyme sites 
Na/K-ATPase activity (umol Pi/mg/h) a2 activity (% of total active enzyme site) 
Ad CMVlacZ 
Ad CMVa2 
4.4 ±0.28 
4.6 ±0.27 
N.D. 
9.8 ±0.4 
Na/K-ATPase activity was measured from six independent membrane preparations, and the values are mean ± standard error. oc2 active sites were 
determined by ouabain binding as in Table 1, and total active enzyme sites were estimated by ATP phosphorylation as described in Section 2. 
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Fig. 4. Comparison of Na/K-ATPase activity as a function of oua-
bain concentration in o¡2 transduced rat liver membranes and con-
trol lacZ transduced liver. Membrane preparations were pre-incu-
bated with different concentrations of ouabain for 15 min, and 
assayed for Na/K-ATPase activity as described in Section 2. Values 
are expressed as mean±S.E. of five independent determinations. 
Note the increased sensitivity of liver membrane Na/K-ATPase ac-
tivity to ouabain following transduction with a2. 
made in vivo; the regulation of Na/K-ATPase activity has 
important implications for cell function and pathophysiology. 
These expression studies were conducted over a 3 day time 
course with LacZ controls to avoid an immune response to 
vector proteins complicating interpretation of the results. Ini-
tial applications of adenoviral vectors have been confounded 
by a lack of true persistence attributed to immune reactions to 
the gene transfer vectors detectable one week after vector in-
fusion. Modified vectors or delivery strategies with immuno-
suppression should lead to an effective long-term gene transfer 
moiety [19-25]. 
These studies support the potential utility of EDRE strat-
egies in conjunction with traditional pharmacological therapy 
(e.g. cardiac glycosides) to alter pathophysiology. Expression 
of the a2 and/or a3 isoforms of Na/K-ATPase is lower in 
heart failure [10-16]. Since these are the ouabain sensitive 
Na/K-ATPase isoforms, their expression may be useful to 
treat heart failure. Escalating doses of ouabain lead to toxic-
ity, primarily in conductive cardiac tissue, so gene therapy 
strategies directed at increasing the relative sensitivity of my-
ocytes to ouabain by expressing the a2 isoform in contractile 
regions of the myocardium in preference to the Purkinje sys-
tem should be of benefit. 
In summary, data reported here document the utility of 
adenovirus vectors to express the «2 isoform in vivo in Wistar 
rat liver; this is significant because other oc2 expression strat-
egies have not proved useful in vivo. Following in vivo ex-
pression, the oc2 isoform dramatically increases membrane 
ouabain sensitivity. It was interesting that transgene derived 
Na/K-ATPase activity down regulates endogenous membrane 
activity to maintain total activity constant. The levels of pro-
tein expression achieved with in vivo adenovirus infusion sug-
gest that delivery of the a2 gene with an adenovirus vector 
might improve the efficacy and therapeutic index of cardiac 
glycosides. 
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